Inventiva Stock Bounces Back 3.88% in Oversold Territory: A Technical Signal to Watch
The stock of the biotech company from Lille gains 3.88% this Friday morning to €4.555, after having closed the previous day at €4.39. This rebound occurs in a context of a weekly decline of 3.5%, while the CAC 40 is slightly up by 0.26% at 8267 points during the session.
This Friday, Inventiva's stock exhibits a notable rebound to €4.555, barely crossing the support threshold identified at €4.39. This level corresponds to the previous day's closing price and the lower boundary of the Bollinger Bands (€4.37), a zone that usually signals a potential oversold situation. The stock is thus trading at the bottom of the band, only 15% above the lower boundary, far from the upper boundary set at €5.64.
The RSI, a momentum indicator that measures the speed and magnitude of price movements, is at 29, just below the conventional threshold of 30, reinforcing the diagnosis of an oversold zone. This technical level could explain the bullish movement observed this morning, in a context where the three-month performance remains positive at +11.23% and where the stock has gained more than 70% over one year. The nearest resistance is at €5.79, about 27% above the current price.
Despite Today's Rebound, Inventiva Remains Below Short and Medium-Term Moving Averages
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
Almost there! Check your inbox.
A confirmation email has been sent. Click the link to confirm your subscription.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Despite today's rebound, Inventiva remains significantly behind its short and medium-term moving averages. The price is below the 20-day moving average (€5.00) and the 50-day moving average (€5.22), indicating a bearish trend over recent weeks. Only the 200-day moving average, established at €4.15, remains below the current price, preserving the long-term bullish trend.
The biopharmaceutical company, specializing in the development of treatments for fibrotic and metabolic diseases, will publish its first quarter 2026 revenue on May 25th. This event will be a focal point for monitoring the progress of its clinical programs. In the health sector, comparables are also up this morning: Sanofi is up 0.52% and UCB advances by 0.96% in session, in a generally stable European context.
Position de trésorerie au 30/09/2025 de 97,6 millions d’euros (plus 24,7 millions d’euros en dépôts à court terme) ; revenus de 4,5 millions d'euros sur les neuf premiers mois de 2025 principalement liés à CTTQ ; flux opérationnels consommés de - 76,3 millions d’euros et flux d'investissement de - 25 millions d’euros ; flux de financement positifs de 103,4 millions d’euros incluant le produit net de la deuxième tranche du financement structuré. Offre publique en novembre 2025 d’ADS apportant un produit net d’environ 139,3 millions d’euros et estimation d’un horizon de trésorerie jusqu’à fin T1 2027 (pouvant aller jusqu’à mi-T3 2027 si exercice intégral de la Tranche 3 pouvant apporter 116,0 millions d'euros).
Risks mentioned
Besoin de capitaux supplémentaires pour financer les opérations
Risque que la Société utilise ses ressources plus rapidement que prévu
Incertitudes et risques liés aux essais cliniques et aux autorisations réglementaires
Dépendance au succès du lanifibranor et des résultats de l'essai NATiV3
Opportunities identified
Produit net de l’offre publique en novembre 2025 d’environ 139,3 millions d’euros renforçant la trésorerie
Exercice potentiel de la Tranche 3 pouvant apporter jusqu’à 116,0 millions d'euros supplémentaires
Paiement d'étape et avoirs liés à l’accord avec CTTQ (10 M$ et 5 M$)
Résultats principaux de l’essai NATiV3 attendus au second semestre 2026
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.